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Organophosphorus (OP) pesticide poisoning is a significant problem worldwide. Research into new antidotes for these
acetylcholinesterase inhibitors, and even optimal doses for current therapies, is hindered by a lack of standardized animal models.
In this study, we sought to characterize the effects of the OP pesticide parathion on acetylcholinesterase in a Wistar rat model
that included comprehensive medical care. Methods. Male Wistar rats were intubated and mechanically ventilated and then
poisoned with between 20mg/kg and 60mg/kg of intravenous parathion. Upon developing signs of poisoning, the rats were treated
with standard critical care, including atropine, pralidoxime chloride, and midazolam, for up to 48 hours. Acetylcholinesterase
activity was determined serially for up to 8 days after poisoning. Results. At all doses of parathion, maximal depression of
acetylcholinesterase occurred at 3 hours after poisoning. Acetylcholinesterase recovered to nearly 50% of baseline activity by day
4 in the 20mg/kg cohort and by day 5 in the 40 and 60mg/kg cohorts. At day 8, most rats’ acetylcholinesterase had recovered to
roughly 70% of baseline. These data should be useful in developing rodent models of acute OP pesticide poisoning.
1. Introduction
Organophosphorus (OPs) pesticides were developed in the
1930s. By the year 2000, approximately 1 billion pounds
of pesticides was used annually in the United States, with
worldwide use estimated to by more than 5.5 billion pounds
[1]. OP pesticides irreversibly bind to and inhibit acetyl-
cholinesterase (AChE). AChE is an enzyme that catalyzes
the breakdown of acetylcholine (Ach) to choline and acetic
acid. During neurotransmission, ACh is released from the
presynaptic neuron into the synaptic cleft and binds to ACh
receptors on the postsynaptic membrane, thereby propagat-
ing the signal from the nerve. AChE (which is located at
the neuromuscular junction, central and peripheral nervous
tissues, and red blood cells) terminates the nerve signal trans-
mission by hydrolyzing ACh [2]. Therefore, AChE inhibition
by OP pesticides leads to a widely dispersed accumulation of
ACh. This increase in ACh manifests acutely as the cholin-
ergic syndrome: bradycardia; central respiratory failure; and
bronchorrhea and bronchospasm [3–5]. To examine the time
course of AChE after OP poisoning, we needed to overcome
this acute cholinergic syndrome. For this reason, the rats
needed to be supported with a mechanical ventilator and
comprehensive medical therapy.
In part because the OP pesticides are used to such a
large degree in developing countries, there is significant
mortality due to OP pesticide poisoning. The World Health
Organization has estimated that more than 3 million people
suffer from pesticide poisoning each year, with a case fatality
rate of up to 10% [6].These numbers do not take into account
estimates that self-poisoning with pesticides accounts for
more than 250,000 deaths per year worldwide, accounting for
about one-third of the world’s suicides [7]. Aside from acute
mortality, it is now known that significant morbidity such
as muscle weakness and neurocognitive dysfunction occurs
after OP pesticide poisoning [8–10].
Part of the difficulty in studying both the acute and
chronic effects ofOPpesticides is the lack of animalmodels of
OP poisoning and infrequent reporting of AChE activity and
variable dosing and formulation of various pesticides [11, 12].
The aim of this investigation was to determine the effect
of AChE of various doses of the highly toxic OP pesticide
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parathion, in order to determine the LD50 of parathion in
a validated OP pesticide poisoning rodent model utilizing
comprehensive intensive care therapy.
2. Material and Methods
Male Wistar rats weighing 200–350 gm (Charles River Labo-
ratories, Wilmington, MA) were housed in pairs, maintained
on 12 : 12 light : dark cycle, and provided food and water ad
libitum. Parathion-ethyl (Sigma-Aldrich, St. Louis, MO) was
administered at three different doses: 20mg/kg, 40mg/kg,
and 60mg/kg. The scientific literature is not consistent when
determining the LD50 of toxic OPs in animal models. For
instance, various strains of rodents have been used; the
OP pesticide has been administered by various routes; and
most importantly, comprehensivemedical therapy (including
mechanical ventilation) has rarely been utilized. It is worth
noting that the LD50 for parathion has been reported to be as
low as 2mg/kg in the rat [13, 14].
Rats were briefly anesthetized for 1-2 minutes with
isoflurane. Once anesthetized, endotracheal intubation was
performedusing a 14- or 16-gaugeTeflon catheter. An internal
jugular catheter of PE-50 tubing was placed and tunneled
subcutaneously to between the scapulae. A 24-gauge catheter
was also placed in a tail vein. General anesthesia was main-
tained with 2–4% isoflurane and oxygenation saturation,
heart rate, noninvasive blood pressure, and temperature (with
feedback to a heating pad) were monitored. Mechanical
ventilation was performed using various rodent ventila-
tors (Harvard Apparatus, Braintree, MA) with intermittent
capnography. Once ventilation was stabilized, parathion was
administered via the jugular vein catheter at a dose of
20mg/kg (20 rats), 40mg/kg (35 rats), or 60mg/kg (37 rats).
When bradycardia developed (defined as a decrease in
heart rate of 50% from baseline) atropine was given as a bolus
dose of either 0.1 or 0.6mg/kg followed by a continuous infu-
sion of either 40 or 250mcg/kg/h via the jugular vein. In order
to mimic a human poisoning scenario, where comprehensive
medical therapy is used, 0.125mg/kg ofmidazolam (Patterson
Veterinary Supply, Devens, MA) was given subcutaneously
and every 4 hours. Pralidoxime chloride (2-PAM, Sigma-
Aldrich, St. Louis, MO) was administered at a dose of either
15mg/kg or 90mg/kg every 6 hours via tail vein. The higher
doses of atropine and pralidoxime were based upon recent
guidance from the NIH to use species-specific modifications
of human medication doses [15]. The pralidoxime dosing
interval was chosen based upon typical dosing regimens
used in the United States. Because pralidoxime is standard
therapy in the United States, the Institutional Animal Care
and Use Committee of the University of Massachusetts
Medical School only approved this study with the utilization
of pralidoxime. Maintenance intravenous fluid of normal
saline (1.5mL/kg/h continuously) via tail vein route was
given and the body temperature of 37-38 degrees Celsius was
maintained throughout.
Twenty-four hours after poisoning the ventilator was
stopped and the rats were extubated. In order to counter-
act the continued cholinergic signs atropine was infused
continuously via the tunneled jugular catheter for another
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Figure 1: Kaplan-Meier survival curves for various doses of intra-
venous parathion.
24–48 hours in an infusion chamber (Instech, Plymouth
Meeting, PA). At day 3 or 4 after poisoning (dependent upon
a rat’s condition), the animal was moved to normal housing
container. Not all rats survived the poisoning model, but
survivors were euthanized at day 8 after poisoning.
Animal ChE Test System Model 610 (EQM Research,
Cincinnati, OH) was used to measure AChE from blood
expressed from the tail vein. The Animal ChE Test System is
a validated desktop AChE measurement system that allows
AChE determination from just 10 𝜇L of blood. The AChE
reagent is >95% specific due to the addition of a specific
inhibitor of plasma butyrylcholinesterase (PChE), As1397
(10-(a-diethylaminopropionyl)-phenothiazine). In order to
minimize any interactions between parathion, pralidoxime,
and AChE, all blood samples were analyzed immediately
upon obtaining the blood.
All statistical analyses were performed with GraphPad
Prism software version 4 (GraphPad Software, San Diego,
CA).
3. Results
Of the 20 rats given 20mg/kg parathion, 10 survived to day
8. At 40mg/kg, 14 rats out of 35 survived, and at 60mg/kg
parathion 9 rats out of 37 survived. Figure 1 is a Kaplan-
Meier survival curve after poisoning with various doses of
parathion.
Of the rats that did not survive parathion doses from 20
to 60mg/kg, nearly all (93%) were dead within 24 hours of
poisoning or proximate to the time of extubation (within 1 to
2 hours). One rat was dead at day 6 in the 40mg/kg parathion
group. Two rats were dead at day 3 and one rat was dead at
day 6 in the 60mg/kg parathion group. Because nonsurviving
rats typically died within 24 hours of poisoning, no further
AChE data could be obtained. However, AChE activity was
neither lower normore rapidly inhibited in the nonsurvivors.
Furthermore, these animals generally looked very weak but
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Figure 2: AChE activity after poisoning with various doses of IV
parathion.
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Figure 3: AChE activity over the first 24 hours after poisoning with
various doses of IV parathion.
did not appear to have more cholinergic signs than surviving
rats.
AChE activity over a period of 8 days after poisoning for
all parathion doses in surviving rats is shown in Figure 2.
AChE recovered to nearly 50% of baseline activity by day 4
in the 20mg/kg cohort and by day 5 in the 40 and 60mg/kg
cohorts. At day 8, most rats’ AChE recovered to roughly 70%
of baseline.
Figure 3 shows AChE activity over the first 24 hours
after parathion poisoning in all rats and for parathion doses
from 20mg/kg to 60mg/kg. All rats were grouped together
regardless of the pralidoxime dose received (either 15 or
90mg/kg), as there was no statistically significant difference
observed in AChE activity based upon dose of pralidoxime
(data not shown).
For all doses studied, AChE decreases to the lowest point
at 3 hours after parathion poisoning. Rats in the 20mg/kg
parathion group began to recover AChE at 12 hours, whereas
rats in the 40 and 60mg/kg groups recovered AChE to a
statistically significant degree at 24 hours after poisoning.
However, the area under the curve (AUC) of AChE activity
over 24 hours was not statistically different among the 20, 40,
or 60mg/kg parathion cohorts.
4. Discussion
Data from these studies demonstrate that in this rat model
AChE activity is inhibited very quickly and in a dose
dependent manner, with a nadir of AChE occurring at
approximately 3 hours after poisoning regardless of the dose
of parathion administered. In animals that were alive 8 days
after poisoning, AChE had only returned to approximately
70% of the baseline activity, regardless of the parathion dose
used. Furthermore, therewas nodifference observed inAChE
activity in animals that received either 15mg/kg or 90mg/kg
2-PAM.
This seeming indifference to the dose of 2-PAM is not
unexpected. The true value of 2-PAM in the treatment of
acute OP poisoning is the subject of significant debate.
Mechanistically, pralidoxime dose reactivates OP-inhibited
AChE and improves neuromuscular transmission in ex vivo
models [16, 17]. However, while pralidoxime has for years
been considered standard therapy for acuteOPpoisoning and
has been shown to be beneficial in some animal models [18]
and human studies of OP poisoning [19], these results are not
universal. For instance, several clinical trials of pralidoxime
have failed to show benefit (or trended towards harm) in
patients acutely poisoned with OP pesticides [20–23]. While
the possible reasons for why pralidoxime may or may not be
beneficial in humans poisoned by OP pesticides are beyond
the scope of this paper, there are certainly many factors
simultaneously at play, including the time from poisoning
to treatment; the type of OP pesticide (e.g., dimethyl versus
diethyl OP); the lipophilicity of the OP pesticide; and the
dose of pralidoxime. Furthermore, there may be a threshold
dose and effect for pralidoxime, and using doses above this
threshold does not improve AChE reactivation.
Few animal models of acute OP pesticide poisoning exist.
This has been particularly true with rodents, and no previous
studies have looked at comprehensive medical therapy to
include mechanical ventilation. This study is important as
it allows us to obtain biochemical and survival data in
rodents treated identically to poisoned humans. Developing
these important animal models has been hindered by the
variability of themodels and the lack of studying or reporting
meaningful data in these models. For example, depending
on the age, gender, and rodent species used, the oral LD50
of parathion has been reported to be between 2mg/kg and
30mg/kg [14]. Such extreme variability makes it virtually
impossible to draw anymeaningful conclusions or to develop
a realistic animal model. We chose our doses of parathion
to span these reported LD50s. Furthermore, LD50s have
been reported in animals exposed to parathion without
any medical therapy. But in order to test new therapies, it
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is important to know what the LD50 is in animals given
comprehensive medical therapy. Lastly, nearly all animal
studies of OP pesticide poisoning fail to report AChE activity.
Thus, until now the true LD50 of parathion during medical
treatment has been unknown.
However, rodent and other models serve a critically
important purpose with acetylcholinesterase inhibitor
research. The US Food and Drug Administration employs
what has been termed the “animal rule” in order to approve
therapies aimed at reducing or preventing serious or life-
threatening conditions caused by exposure to a “permanently
disabling toxic agent,” such asOP pesticides, in which human
efficacy trials are not possible or ethical [12]. Based on this
animal rule, the FDA may rely exclusively on animal efficacy
studies to provide evidence of therapeutic [24]. While the
animal rule is relatively new and underutilized for drug
deployment, it was invoked by the FDA in 2003 for the
approval of pyridostigmine bromide as a pretreatment for
nerve agent exposure in military personnel [25].
As expected with any toxin, there was a dose dependent
decrease in survival in this model, even with critical care
support. At a parathion dose of 20mg/kg, exactly one-half of
animals survived to 24 hours and to 8 days after poisoning.
At a dose of 60mg/kg parathion 24.3% of animals survived:
thus the LD75 for IV parathion is approximately 60mg/kg.
This is important, as is toxicology survival research in animal
models: a toxin dose of greater than a single LD50 is needed in
order to detect clinically and statistically meaningful results
with aminimal number of animals. It appears that 3x LD50 of
parathion (i.e., 60mg/kg intravenously) may be a reasonable
dose for further survival studies.
5. Conclusion
In the Wistar rat, parathion inhibits AChE in a dose depen-
dent manner, with the AChE nadir occurring at approxi-
mately 3 hours after IV parathion administration regardless
of the parathion dose used. Using comprehensive critical
care therapy, including mechanical ventilation, atropine,
pralidoxime, and midazolam, the IV LD50 for parathion
is approximately 20mg/kg. These data will be useful for
investigators developing models of acute OP poisoning and
studying treatment algorithms for acute poisoning.
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